Tgf beta receptor antagonists

A compound having the structure of formula (I)

• or a pharmaceutically acceptable salt, prodrug, or N-oxide thereof, or a solvate or hydrate thereof,
• wherein
• A is a 5-8 membered heterocyclic ring or a 10-12 membered heterobicyclic ring substituted with 0-3 R4 groups containing 1-4 heteroatoms selected from —O—, —S— or —N—;
• each R4 is independently hydrogen, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C3-C6 cycloalkyl, —NH2, —NO2, or —CN;
• Z is a 10-12 membered heterobicyclic ring substituted with 0-2 RZ groups containing 1-4 heteroatoms selected from —O—, —S— or —N—;
• each RZ is independently halogen, —CN, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 alkenyl, C3-C6 cycloalkyl, C1-C6 alkoxy, C1-C6 alkanol, —COO C1-C6 alkyl, —CONRz1Rz2, —NHC(O) C1-C6 haloalkyl, —NHC(O) C1-C6 alkyl, —NH C1-C6 alkyl or a 5-8 membered heterocyclic ring substituted with 0-3 R4 groups containing 1-4 heteroatoms selected from —O—, —S— or —N—;
• each Rz1 and Rz2 is independently hydrogen, C1-C6 alkyl or C3-C6 cycloalkyl;
• R1 is hydrogen, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 alkanol, C1-C6 haloalkyl, C1-C6 alkyloxy, C3-C6 cycloalkyl substituted with 0-2 R4 groups, CONR1aR1b, —NHC(O) C1-C6 alkyl, —COOH, —COO C1-C6 alkyl or a 5-8 membered heterocyclic ring substituted with 0-3 R4 groups containing 1-4 heteroatoms selected from —O—, —S— or —N—;
• each R1a and R1b is independently hydrogen, C1-C6 alkyl or C3-C6 cycloalkyl;
• and
• R2 is hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkyloxy, C3-C8 cycloalkyl or —NHC(O) C1-C6 alkyl.